JP2010227101A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010227101A5 JP2010227101A5 JP2010101904A JP2010101904A JP2010227101A5 JP 2010227101 A5 JP2010227101 A5 JP 2010227101A5 JP 2010101904 A JP2010101904 A JP 2010101904A JP 2010101904 A JP2010101904 A JP 2010101904A JP 2010227101 A5 JP2010227101 A5 JP 2010227101A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- crl1005
- bak
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 229960000686 benzalkonium chloride Drugs 0.000 claims 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 6
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 3
- 230000001900 immune effect Effects 0.000 claims 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940028617 conventional vaccine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43554902P | 2002-12-23 | 2002-12-23 | |
| US60/435,549 | 2002-12-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563851A Division JP2006511221A (ja) | 2002-12-23 | 2003-12-19 | ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010227101A JP2010227101A (ja) | 2010-10-14 |
| JP2010227101A5 true JP2010227101A5 (enExample) | 2010-12-16 |
| JP5129292B2 JP5129292B2 (ja) | 2013-01-30 |
Family
ID=32682258
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563851A Pending JP2006511221A (ja) | 2002-12-23 | 2003-12-19 | ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン |
| JP2010101904A Expired - Fee Related JP5129292B2 (ja) | 2002-12-23 | 2010-04-27 | ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563851A Pending JP2006511221A (ja) | 2002-12-23 | 2003-12-19 | ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US7410795B2 (enExample) |
| EP (2) | EP2311848B1 (enExample) |
| JP (2) | JP2006511221A (enExample) |
| AT (1) | ATE471335T1 (enExample) |
| AU (1) | AU2003301148A1 (enExample) |
| CA (2) | CA2508228C (enExample) |
| DE (1) | DE60333035D1 (enExample) |
| DK (1) | DK2311848T3 (enExample) |
| ES (1) | ES2429338T3 (enExample) |
| PT (1) | PT2311848E (enExample) |
| SI (1) | SI2311848T1 (enExample) |
| WO (1) | WO2004058166A2 (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| JP4800485B2 (ja) * | 1999-03-26 | 2011-10-26 | バイカル インコーポレイテッド | ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法 |
| US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
| EP1578193A4 (en) * | 2002-12-23 | 2011-06-15 | Vical Inc | FREEZING PROCESS FOR NUCLEIC ACID / BLOCK COPOLYMER / CATION SIDE COMPLEXES |
| WO2004060363A1 (en) * | 2002-12-23 | 2004-07-22 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
| PT2311848E (pt) * | 2002-12-23 | 2013-10-03 | Vical Inc | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
| EP1607485A1 (en) * | 2004-06-14 | 2005-12-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for quantifying VEGF121 isoform in a biological sample |
| WO2006060723A2 (en) * | 2004-12-03 | 2006-06-08 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
| CN1307423C (zh) * | 2005-01-08 | 2007-03-28 | 王明丽 | 重组抗原pp65包被酶标反应板的制法及ELISA检测试剂盒 |
| JP2006223194A (ja) * | 2005-02-17 | 2006-08-31 | Tosoh Corp | スタニオカルシン１（ＳＴＣ１）ｍＲＮＡの測定方法 |
| CA2598884A1 (en) * | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| MX357691B (es) | 2006-01-13 | 2018-07-19 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And | Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas. |
| US9182398B2 (en) | 2006-04-01 | 2015-11-10 | Medical Service Consultation International, Llc | Methods and compositions for detecting fungi and mycotoxins |
| US9476032B2 (en) * | 2007-03-30 | 2016-10-25 | The Research Foundation For The State University Of New York | Attenuated viruses useful for vaccines |
| US20090004203A1 (en) * | 2007-05-29 | 2009-01-01 | Vical Incorporated | Methods of treating measles infectious disease in mammals |
| US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| EP2313503A4 (en) * | 2008-08-01 | 2014-01-08 | Merck Sharp & Dohme | Variant HCMV-PP65, IE1 and IE2 polynucleotides, and uses thereof |
| US20100068718A1 (en) | 2008-08-22 | 2010-03-18 | Hooper Dennis G | Methods and Compositions for Identifying Yeast |
| WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| PL3178490T3 (pl) | 2009-07-15 | 2022-08-01 | Glaxosmithkline Biologicals S.A. | Kompozycje białka f rsv i sposoby ich wytwarzania |
| JP5833443B2 (ja) * | 2009-08-29 | 2015-12-16 | 株式会社バイオメッドコア | 抗原特異的ｔ細胞誘導能測定法 |
| US8962251B2 (en) | 2009-10-08 | 2015-02-24 | Medical Service Consultation International, Llc | Methods and compositions for identifying sulfur and iron modifying bacteria |
| US8802106B2 (en) * | 2009-10-30 | 2014-08-12 | The Administrators Of The Tulane Educational Fund | Peptide compositions and methods for inhibiting herpesvirus infection |
| US20110256535A1 (en) * | 2010-02-11 | 2011-10-20 | Intelligent Medical Devices, Inc. | Optimized oligonucleotides and methods of using same for the detection, isolation, amplification, quantification, monitoring, screening and sequencing of clostridium difficile genes encoding toxin b, and/or toxin a and/or binary toxin |
| RS54489B1 (sr) | 2010-07-06 | 2016-06-30 | Glaxosmithkline Biologicals Sa | Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| JP5940064B2 (ja) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | 低用量のｒｎａを用いた大型哺乳動物の免疫化 |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| DK2590676T3 (en) | 2010-07-06 | 2016-10-24 | Glaxosmithkline Biologicals Sa | Virionlignende feed particles to self-replicating RNA molecules |
| SMT202200311T1 (it) | 2010-08-31 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Liposomi pegilati per somministrare rna codificante un immunogene |
| US9127321B2 (en) * | 2010-10-06 | 2015-09-08 | The Translational Genomics Research Institute | Method of detecting Coccidioides species |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| PL2667892T3 (pl) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | Schemat szczepień przeciwko rsv |
| ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| EP3508219A1 (en) | 2011-07-06 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Self-replicating rna prime - protein boost vaccines |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| CN103781470A (zh) | 2011-07-06 | 2014-05-07 | 诺华股份有限公司 | 包含核酸的水包油乳液 |
| TWI570240B (zh) | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| AU2012322704B2 (en) | 2011-10-11 | 2017-09-07 | Novartis Ag | Recombinant self-replicating polycistronic RNA molecules |
| AU2012335277B2 (en) | 2011-11-11 | 2018-06-14 | Variation Biotechnologies Inc. | Compositions and methods for treatment of cytomegalovirus |
| WO2013144722A2 (en) | 2012-03-27 | 2013-10-03 | Variation Biotechnologies, Inc. | Methods for detection of anti-cytomegalovirus neutralizing antibodies |
| CN104853770A (zh) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 免疫原性组合物及其应用 |
| JP6199965B2 (ja) | 2012-07-11 | 2017-09-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療 |
| EP2904119B1 (en) | 2012-10-02 | 2020-06-17 | The General Hospital Corporation d/b/a Massachusetts General Hospital | Methods relating to dna-sensing pathway related conditions |
| CN109045294A (zh) | 2013-01-10 | 2018-12-21 | 思齐乐 | 流感病毒免疫原性组合物及其应用 |
| EP2765137A1 (en) | 2013-02-07 | 2014-08-13 | Sanofi Pasteur | Induction of cross-reactive cellular response against rhinovirus antigens |
| US9603379B2 (en) | 2013-03-15 | 2017-03-28 | Applied Food Biotechnology, Inc | Feline bitter taste receptors and methods |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3556353A3 (en) | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| WO2017011773A2 (en) * | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CA3002819A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| JP6925688B2 (ja) | 2015-10-22 | 2021-08-25 | モデルナティーエックス， インコーポレイテッド | 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| KR102526506B1 (ko) | 2016-07-08 | 2023-05-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물 |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| EP3939604A3 (en) | 2016-10-21 | 2022-06-22 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| WO2018151816A1 (en) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| JP7235676B2 (ja) | 2017-05-17 | 2023-03-08 | ザ ジェネラル ホスピタル コーポレイション | 結節性硬化症の遺伝子治療 |
| US11141377B2 (en) | 2017-06-15 | 2021-10-12 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| MA51230A (fr) | 2018-01-29 | 2021-05-05 | Merck Sharp & Dohme | Protéines f rsv stabilisées et leurs utilisations |
| CN109082413B (zh) * | 2018-09-18 | 2023-01-10 | 四川安可瑞新材料技术有限公司 | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| EP4103227A1 (en) | 2020-02-14 | 2022-12-21 | Merck Sharp & Dohme LLC | Hpv vaccine |
| CN116096430A (zh) | 2020-04-27 | 2023-05-09 | 衣阿华大学研究基金会 | 用于治疗囊性纤维化的组合物和方法 |
| WO2021224633A1 (en) | 2020-05-06 | 2021-11-11 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022051023A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Live-attenuated rna hybrid vaccine technology |
| WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
| WO2022051024A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Genetically-adjuvanted rna vaccines |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| EP4323525A2 (en) | 2021-04-16 | 2024-02-21 | Genentech, Inc. | Optimized tlr7 ligands and uses thereof |
| JP2024522943A (ja) | 2021-06-14 | 2024-06-21 | ブリッジバイオ ジーン セラピー リサーチ， インコーポレイテッド | 結節性硬化症に対する遺伝子療法 |
| AU2022327583A1 (en) | 2021-08-11 | 2024-02-22 | King's College London | Compositions and methods for improved treatment of disorders affecting the central nervous system |
| CN118019547A (zh) | 2021-08-19 | 2024-05-10 | 默沙东有限责任公司 | 热稳定脂质纳米粒子及其使用方法 |
| WO2023228116A1 (en) | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
| EP4583841A1 (en) | 2022-09-09 | 2025-07-16 | Access to Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
| EP4594505A1 (en) | 2022-09-30 | 2025-08-06 | Centre National de la Recherche Scientifique | Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations |
| WO2024147114A1 (en) | 2023-01-06 | 2024-07-11 | Bloomsbury Genetic Therapies Limited | Compositions and methods for treating parkinson's disease |
| EP4709417A2 (en) | 2023-05-08 | 2026-03-18 | Merck Sharp & Dohme LLC | Polynucleotides encoding norovirus vp1 antigens and uses thereof |
| KR20260021734A (ko) | 2023-06-09 | 2026-02-13 | 머크 샤프 앤드 돔 엘엘씨 | 인간 유두종바이러스 백신을 위한 나노에멀젼 아주반트 조성물 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6100064A (en) * | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| US6242567B1 (en) * | 1984-07-27 | 2001-06-05 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
| US6133433A (en) * | 1984-07-27 | 2000-10-17 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US6162620A (en) | 1986-03-07 | 2000-12-19 | Cogent Limited | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor |
| US5124440A (en) * | 1986-11-24 | 1992-06-23 | The Childrens Hospital, Inc. | Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus |
| JP2607712B2 (ja) | 1988-01-29 | 1997-05-07 | カイロン コーポレイション | 組換えｃｍｖ中和タンパク |
| US5547834A (en) * | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6174666B1 (en) * | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
| US5837693A (en) | 1995-03-24 | 1998-11-17 | The Regents Of The University Of California | Intravenous hormone polypeptide delivery by salivary gland expression |
| US5885971A (en) | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
| US5721354A (en) * | 1995-03-31 | 1998-02-24 | Aviron | Human cytomegalovirus DNA sequences |
| US5800981A (en) * | 1996-02-22 | 1998-09-01 | University Of Limburg | Human cytomegalovirus antigen and its use |
| US6020481A (en) | 1996-04-01 | 2000-02-01 | The Perkin-Elmer Corporation | Asymmetric benzoxanthene dyes |
| WO1997040165A1 (en) | 1996-04-23 | 1997-10-30 | The Wistar Institute Of Anatomy And Biology | Novel human cytomegalovirus dna constructs and uses therefor |
| FR2753512B1 (fr) * | 1996-09-19 | 1998-12-31 | Sachs Ind Sa | Chaine de transmission notamment pour cycle |
| US6156317A (en) | 1996-11-12 | 2000-12-05 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6074645A (en) * | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| EP1002091B1 (en) * | 1997-07-09 | 2012-02-29 | Coridon Pty Limited | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| KR100239879B1 (ko) * | 1997-11-05 | 2000-02-01 | 김상조 | 간암 예방 및 치료용 생약제 |
| JP3253590B2 (ja) * | 1998-08-31 | 2002-02-04 | シャープ株式会社 | ハーフトーンマスクの製造方法 |
| JP4800485B2 (ja) | 1999-03-26 | 2011-10-26 | バイカル インコーポレイテッド | ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法 |
| FR2804028B1 (fr) * | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
| US6835383B2 (en) * | 2000-03-23 | 2004-12-28 | City Of Hope | Protein kinase deficient, immunologically active CMVpp65 mutants |
| US6875748B2 (en) | 2000-04-21 | 2005-04-05 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
| DE60026199T2 (de) | 2000-05-18 | 2006-11-23 | Geneart Ag | Synthetische Gene für gagpol und deren Verwendungen |
| EP1335953A4 (en) * | 2000-06-23 | 2005-03-30 | Merck & Co Inc | POLYNUCLEOTIDE VACCINE ADJUVANZIA AND FORMULATIONS CONTAINING CATIONIC SURFACTANTS AND ITS USES |
| US20020110567A1 (en) * | 2000-08-10 | 2002-08-15 | Volker Gerdts | In utero oral nucleic acid immunization |
| PT2311848E (pt) * | 2002-12-23 | 2013-10-03 | Vical Inc | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
| US20050283146A1 (en) | 2004-06-17 | 2005-12-22 | Lentz David J | Thermally extended spiral cryotip for a cryoablation catheter |
-
2003
- 2003-12-19 PT PT100062272T patent/PT2311848E/pt unknown
- 2003-12-19 AT AT03814236T patent/ATE471335T1/de not_active IP Right Cessation
- 2003-12-19 US US10/738,986 patent/US7410795B2/en not_active Expired - Fee Related
- 2003-12-19 DK DK10006227.2T patent/DK2311848T3/da active
- 2003-12-19 SI SI200332305T patent/SI2311848T1/sl unknown
- 2003-12-19 EP EP10006227.2A patent/EP2311848B1/en not_active Expired - Lifetime
- 2003-12-19 CA CA2508228A patent/CA2508228C/en not_active Expired - Fee Related
- 2003-12-19 AU AU2003301148A patent/AU2003301148A1/en not_active Abandoned
- 2003-12-19 ES ES10006227T patent/ES2429338T3/es not_active Expired - Lifetime
- 2003-12-19 JP JP2004563851A patent/JP2006511221A/ja active Pending
- 2003-12-19 DE DE60333035T patent/DE60333035D1/de not_active Expired - Lifetime
- 2003-12-19 EP EP03814236A patent/EP1587816B1/en not_active Expired - Lifetime
- 2003-12-19 CA CA2756797A patent/CA2756797C/en not_active Expired - Fee Related
- 2003-12-19 WO PCT/US2003/040685 patent/WO2004058166A2/en not_active Ceased
-
2007
- 2007-08-17 US US11/892,020 patent/US7888112B2/en not_active Expired - Fee Related
-
2010
- 2010-04-27 JP JP2010101904A patent/JP5129292B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-25 US US13/013,752 patent/US8278093B2/en not_active Expired - Fee Related
-
2012
- 2012-06-18 US US13/525,814 patent/US8673317B2/en not_active Expired - Fee Related
-
2014
- 2014-02-10 US US14/176,813 patent/US9180162B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010227101A5 (enExample) | ||
| CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
| CN103998604B (zh) | Hbv聚合酶突变体 | |
| JP2016534034A5 (enExample) | ||
| AU2017207764A1 (en) | Means and methods for treating HBV | |
| JP2017522907A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2008529558A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| TW201602347A (zh) | 對抗腸病毒感染之基於腺病毒載體之疫苗 | |
| JP2016513471A5 (enExample) | ||
| EP3342866B1 (en) | Polypeptide carrier for presenting target polypeptide and uses thereof | |
| KR20200100745A (ko) | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 | |
| JP2025084850A (ja) | ハンタウイルス抗原性組成物 | |
| JP5188400B2 (ja) | Ｃ型肝炎ウイルスの非構造融合タンパク質 | |
| EP4183409A1 (en) | Vaccine with improved immunogenicity against mutant coronaviruses | |
| CA2795308A1 (en) | Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus | |
| JP2014534262A5 (enExample) | ||
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| US20160228531A1 (en) | Treatment of hepatitis d virus infections by redirection of t cells | |
| US20230331782A1 (en) | Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease | |
| CA3023706C (en) | Adeno-associated virus particle with mutated capsid and methods of use thereof | |
| Liang et al. | 3′-UTR sequence of Macrobrachium rosenbergii extra small virus (XSV) is important for viral RNA packaging | |
| CN116888139A (zh) | 诱导高水平i型干扰素的新型复制缺陷型甲型流感病毒 |